Drugs / BI 3006337
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06310005 | Apr → Oct 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05970640 | Aug 2023 → Oct 2024 | NAFLD1, obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05076422 | Oct 2021 → Mar 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 3006337 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05076422 ↗ |
| Route | Subcutaneous | “administered once as a single dose subcutaneously” NCT05076422 ↗ |